The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
|Videos|September 26, 2016
- Hematologic Malignancies: Polycythemia Vera
- Volume 3
- Issue 3
Significant Developments in Treating PV
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, discusses the most recent developments in diagnosing polycythemia vera.
Advertisement
Articles in this issue
about 10 years ago
Differences Between Polycythemia Vera and Essential Thrombocythemiaabout 10 years ago
Experts Debate Need for New Drugs to Treat Patients with PV and ETabout 10 years ago
Management of ET, PV Requires 2 Distinct Approachesabout 10 years ago
Expert Discusses Recent Developments in Polycythemia Veraabout 10 years ago
Ruxolitinib Beats Out Best Available Therapy in Polycythemia VeraAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5